What is Roka Bioscience?
Headquartered in Warren, New Jersey, Roka Bioscience operates at the intersection of biotechnology and food safety. The company specializes in the development and commercialization of advanced molecular assay technologies designed to identify foodborne pathogens with high precision. Central to its market offering is the Atlas instrument, a fully automated platform that streamlines diagnostic workflows by eliminating traditional batch processing requirements. This integrated system supports a suite of detection assays for critical contaminants, including Salmonella, Listeria, and E. coli. By serving a diverse client base that encompasses food processors, third-party testing laboratories, and government regulatory bodies, Roka Bioscience has established a robust footprint in the diagnostic testing market, effectively replacing manual, labor-intensive processes with high-throughput, automated molecular solutions.
How much funding has Roka Bioscience raised?
Roka Bioscience has raised a total of $150M across 4 funding rounds:
Series C
$20M
Series D
$47.5M
Stock Offering
$60M
Share Placement
$22.5M
Series C (2011): $20M with participation from OrbiMed, TPG Biotech, Gen-Probe, and New Enterprise Associates
Series D (2012): $47.5M led by New Enterprise Associates, OrbiMed, TPG Biotech, and Aisling Capital
Stock Issuance/Offering (2014): $60M, investors not publicly disclosed
Share Placement (2016): $22.5M, investors not publicly disclosed
Key Investors in Roka Bioscience
New Enterprise Associates
Established in 1977 and headquartered in Menlo Park, California. New Enterprise Associates(NEA) is a venture capital firm focused on helping entrepreneurs build businesses.
OrbiMed
OrbiMed Advisors LLC operates as a specialized investment firm focused on the healthcare sector, with deep expertise spanning multiple therapeutic and commercial domains.
TPG Biotech
TPG is a global alternative asset management firm founded in 1992 with investment strategies spanning private equity, growth equity, impact investing, real estate, market solutions and credit.
What's next for Roka Bioscience?
With the infusion of capital from its most recent strategic round, Roka Bioscience is well-positioned to accelerate the adoption of its Atlas platform across global food supply chains. The company's strategic roadmap likely involves expanding its assay menu to address emerging pathogen threats and deepening its penetration into international regulatory markets. As the demand for rapid, accurate food safety testing continues to rise, Roka Bioscience's focus on operational efficiency and technological integration will be pivotal in maintaining its competitive advantage. Future growth will likely hinge on the company's ability to leverage its existing diagnostic infrastructure to capture additional market share within the contract testing laboratory segment, further solidifying its role as a cornerstone of modern food safety protocols.
See full Roka Bioscience company page
